The purpose of this phase II study is to evaluate the efficacy and safety of Bacopa monnieri
standardized extract (300 mg/day) taken for 12 weeks in 264 veterans with GWI, and to gain
insight into the underlying biological mechanisms of nootropic, anti-inflammatory, and
adaptogenic actions tied to Bacopa.